ClinicalTrials.gg
CompletedNCT00277160Updated Oct 8, 2010

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

A Phase 4 interventional study of Neulasta (pegfilgrastim) in Neutropenia, Breast Cancer and Lung Cancer, sponsored by Amgen. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2010-10-08.

Sponsored by Amgen · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
2nd of 28
852 · median 121
Started
2002
with 4 others
Phase 4
3 of 33
none open now
Registered
14th of 33
by date
Lead sponsor
10 of 33
Amgen

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2002, is one of 3 in phase 4, and was the 14th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older patients receiving chemotherapy.

03

Conditions studied

  • Neutropenia
  • Breast Cancer
  • Lung Cancer
  • Non-Hodgkin's Lymphoma
  • Ovarian Cancer
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >/= 65 years old
  • documented diagnosis of lung, breast, or ovarian cancer, or NHL
  • scheduled to receive one of 15 standard chemotherapy regimens
  • chemotherapy naive OR have received therapy AND/OR have no more than one regimen of chemotherapy for disease
  • of at least 3 months
  • performance status \</=2
  • adequate renal and hematologic function
  • for participation in the study prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • known to any of the products to be administered during dosing
  • primary prophylactic antibiotics in all cycles
  • prior radiation therapy within 2 weeks of randomization into this study or plan for radiation therapy during study participation, except for spot radiation for bony
  • prior bone marrow or stem cell transplant or plan to receive any transplant therapy during study participation
  • clinically symptomatic
  • Folstein score \<18
  • Any premalignant myeloid condition or any with myeloid characteristics
  • History of prior malignancy within the last 5 years other than subject's original cancer diagnosis listed in inclusion criteria with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, in situ cervical carcinoma or surgically cured malignancies
  • unstable/uncontrolled cardiac conditions or hypertension
  • active infection
  • subject is currently enrolled or has not yet completed at least 30 days since ending other device or drug trial or is receiving other investigational agents
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
852 participants (actual)

Study arms

  • Experimental
    Treatment Group 1 (Primary Prophylaxis)

    Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1

    Drug: Neulasta (pegfilgrastim)

  • Active comparator
    Treatment Group 2 (Secondary Prophylaxis)

    Per Investigator's discretion

    Drug: Neulasta (pegfilgrastim)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of febrile neutropenia, defined by ANC < 1.0 x 10^9/L and temperature ≥ 38o C on the same day

    Time frame: End of the last cycle of chemotherapy or the date of early termination from the study

Secondary outcomes

  1. Incidence of grade 3 and 4 neutropenia

    Time frame: End of the last cycle of chemotherapy or the date of early termination from the study

  2. Dose delays or dose reductions

    Time frame: End of the last cycle of chemotherapy or the date of early termination from the study

  3. Incidence of febrile neutropenia with a more strict definition (ANC < 0.5 x 10^9/L and temperature ≥ 38o C), on the same day

    Time frame: End of the last cycle of chemotherapy or the date of early termination from the study

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007 Dec;12(12):1416-24. doi: 10.1634/theoncologist.12-12-1416. PubMed 18165618 ↗
  • Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs. 2010 Feb;14(1):81-6. doi: 10.1188/10.CJON.81-86. PubMed 20118030 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Nov 2004 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2006
First posted
Jan 16, 2006
Start
Jun 2002
Primary completionActual
Nov 2004
CompletionActual
Jan 2005
Last update
Oct 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00277160
Lead sponsor
Amgen
First posted
Jan 16, 2006
Start date
Jun 2002
Primary completion
Nov 2004
Completion
Jan 2005
Last update
Oct 8, 2010

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion